Home » Stocks » Avenue Therapeutics

Avenue Therapeutics, Inc. (ATXI)

Stock Price: $9.90 USD 0.20 (2.06%)
Updated Jul 8, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 165.16M
Revenue (ttm) n/a
Net Income (ttm) -15.88M
Shares Out 16.68M
EPS (ttm) -0.97
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 8, 2020
Last Price $9.90
Previous Close $9.70
Change ($) 0.20
Change (%) 2.06%
Day's Open 9.72
Day's Range 9.51 - 9.96
Day's Volume 46,834
52-Week Range 4.96 - 11.83

More Stats

Market Cap 165.16M
Enterprise Value 158.59M
Earnings Date (est) Aug 12, 2020
Ex-Dividend Date n/a
Shares Outstanding 16.68M
Float 5.55M
EPS (basic) -0.98
EPS (diluted) -0.97
FCF / Share -1.39
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 49,287
Short Ratio 0.94
Short % of Float 2.03%
Beta 0.20
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 29.24
Revenue n/a
Operating Income -16.18M
Net Income -15.88M
Free Cash Flow -22.86M
Net Cash 6.57M
Net Cash / Share 0.39
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -55.47%
ROE -121.58%
ROIC -1,619.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(26.26% upside)
Current: 9.90
Target: 12.50
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-26.27-21.64-11.42-2.38-4.84
Net Income-25.91-21.55-12.26-3.18-5.23
Shares Outstanding15.7210.246.632.862.70
Earnings Per Share-1.65-2.10-1.85-1.11-1.93
Operating Cash Flow-26.26-18.22-6.80-1.63-0.90
Free Cash Flow-26.26-18.22-6.80-1.63-0.90
Cash & Equivalents8.752.6721.780.200.01
Total Debt---5.873.87
Net Cash / Debt8.752.6721.78-5.68-3.85
Book Value6.80-0.6319.38-8.25-5.14
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Avenue Therapeutics, Inc.
Country United States
Employees 4
CEO Lucy Lu

Stock Information

Ticker Symbol ATXI
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ATXI
IPO Date June 27, 2017


Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain. The company was founded in 2015 and is based in New York, New York. Effective as of December 31, 2019, Avenue Therapeutics, Inc. operates as a subsidiary of InvaGen Pharmaceuticals, Inc.